Malignant neoplasm of anterior wall of nasopharynx
ICD-10 C11.3 is a billable code used to indicate a diagnosis of malignant neoplasm of anterior wall of nasopharynx.
C11.3 refers to a malignant neoplasm located specifically in the anterior wall of the nasopharynx, which is the upper part of the throat behind the nose. This type of cancer is often associated with risk factors such as Epstein-Barr virus (EBV) infection and, in some cases, human papillomavirus (HPV). The nasopharynx is a critical area for both respiratory and digestive functions, and malignancies here can lead to significant complications, including obstruction of airflow and swallowing difficulties. Symptoms may include nasal obstruction, epistaxis (nosebleeds), and otitis media due to Eustachian tube dysfunction. Diagnosis typically involves imaging studies such as MRI or CT scans, along with biopsy for histological confirmation. Treatment often includes radiation therapy, which is the primary modality for localized disease, and may be combined with chemotherapy for advanced cases. The prognosis varies based on the stage at diagnosis and the patient's overall health.
Detailed descriptions of tumor location, size, and histological type.
Patients presenting with nasal obstruction, hearing loss, or neck masses.
Documentation must clearly indicate the relationship between symptoms and the neoplasm.
Comprehensive treatment plans including chemotherapy and radiation details.
Management of advanced nasopharyngeal cancer with multimodal therapy.
HPV status should be documented as it may affect prognosis and treatment.
Used for evaluating suspected nasopharyngeal malignancy.
Document indications for the procedure and findings.
Otolaryngologists should ensure thorough documentation of findings.
Used in the treatment of nasopharyngeal cancer.
Document treatment plan and response to therapy.
Oncologists must document the radiation field and dosage.
HPV status can influence treatment decisions and prognosis. HPV-positive tumors may respond differently to treatment compared to HPV-negative tumors, making it essential to document this status.
When coding for radiation therapy, ensure that C11.3 is linked to the treatment provided, including the type of radiation and the area treated.
